Atenolol Market Share

North American Market Forecast

The market share of atenolol in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 40% by the end of 2036. The growth of the market can be attributed majorly to the increasing prevalence of cardiac diseases, along with the rising frequency of hypertension in the region. For instance, approximately 1 in every 18 people, or 5% of the U.S. population has arrhythmia. Furthermore, as per the statistics by the Centers for Disease Control and Prevention, in the U.S., 116 million individuals have hypertension, and in 2019, 0.5 million deaths were caused directly or indirectly by hypertension. In addition to this, the increasing availability of advanced treatment and medications, followed by the surge in healthcare expenditure is also projected to drive the growth of the atenolol market further during the projected time frame in the region.

APAC Market Statistics

The Asia Pacific atenolol market is estimated to be the second largest, registering a share of about 28% by the end of 2036. The growth of the market can be attributed majorly to the rising burden of hypertension, coupled with the surge in population, and changing lifestyle of people in the region. Besides this, the growing awareness in people regarding the use of hypertension drugs is also a significant factor anticipated to drive market growth in the region during the forecast period. In addition to this, an increase in inappropriate diet habits, coupled with the surge in fast food consumption is also estimated to drive market growth in the APAC region during the forecast period.

Europe Market Forecast

Further, the market in Europe, amongst the market in all the other regions, is projected to hold a noteworthy share of about 17% by the end of 2036. The growth of the market can be attributed majorly, as the region has witnessed a sharp hike in the cases of cardiovascular diseases. For instance, every year, more than 1.6 million deaths in the European Union and 4 million deaths in Europe are attributed to cardiovascular diseases. Moreover, efficient and inexpensive healthcare facilities in European countries are estimated to support the growth of the market. In addition to this, the surge in the life science sector is also estimated to drive the growth of the atenolol market in the European region.